<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03163667</url>
  </required_header>
  <id_info>
    <org_study_id>CX-839-005</org_study_id>
    <nct_id>NCT03163667</nct_id>
  </id_info>
  <brief_title>ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC</brief_title>
  <acronym>ENTRATA</acronym>
  <official_title>ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calithera Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calithera Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 Study Comparing CB-839 in Combination with Everolimus (CBE) vs. Placebo with
      Everolimus (PboE) in Patients with Advanced or Metastatic RCC
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination
      with Everolimus (CBE) vs. Placebo with Everolimus (PboE) in Patients with Advanced or
      Metastatic Renal Cell Carcinoma (RCC)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a double blinded placebo-controlled study where patients will be randomized 2:1 to either CB-839 plus everolimus (CBE) or placebo plus everolimus (PboE)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blinded, placebo-controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>30 months</time_frame>
    <description>Assessed by Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>42 months</time_frame>
    <description>Assessed by time from randomization to death by any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>CB-839 plus everolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CBE: CB-839 is administered twice daily in combination with standard doses of everolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus everolimus</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PboE: Placebo is administered twice daily in combination with standard doses of everolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-839 plus everolimus</intervention_name>
    <description>CB-839 is administered as oral tablets twice daily (BID) in combination with standard daily (QD) everolimus in 28 day cycles.</description>
    <arm_group_label>CB-839 plus everolimus</arm_group_label>
    <other_name>Affinitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo plus everolimus</intervention_name>
    <description>Placebo is administered as oral tablets twice daily (BID) in combination with standard daily (QD) everolimus in 28 day cycles.</description>
    <arm_group_label>Placebo plus everolimus</arm_group_label>
    <other_name>Affinitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Karnofsky Performance Score (KPS) ≥ 70%

          -  Estimated Life Expectancy of at least 3 mo

          -  Documented histological or cytological diagnosis of renal cell carcinoma with a
             clear-cell component.

          -  Measurable Disease per RECIST 1.1 as determined by the Investigator

          -  Must have received at least two prior lines of systemic therapy, including at least
             one VEGFR-targeting TKI (e.g., sunitinib, sorafenib, pazopanib, cabozantinib)

             a) For the most recently received VEGFR-targeting TKI there must have been progression
             of disease as determined by the treating physician either (i) during treatment or (ii)
             within 6 mo following completion of at least 4 weeks of treatment with the TKI

          -  Must have received at least one of cabozantinib or nivolumab (or other active
             anti-PD-1/PD-L1 therapy)

          -  Prior treatment with other anti-cancer therapies including cytokines, monoclonal
             antibodies, immunotherapies, and cytotoxic chemotherapy is allowed

        Exclusion Criteria:

          -  Prior treatment with mTOR inhibitors (everolimus or temsirolimus) or CB-839

          -  Receipt of any anticancer therapy within the following windows before randomization:

               -  TKI therapy within 2 weeks or 5 half-lives, whichever is shorter.

               -  Any type of anti-cancer antibody within 4 weeks

               -  Cytotoxic chemotherapy within 4 weeks

               -  Investigational therapy within 4 weeks or 5 half-lives whichever is shorter

               -  Radiation therapy for bone metastasis within 2 weeks, any other external
                  radiation therapy within 4 weeks before randomization. Patients with clinically
                  relevant ongoing complications from prior radiation therapy are not eligible.

          -  Unable to receive medications PO or any condition that may prevent adequate absorption
             of oral study medication including refractory nausea and vomiting, uncontrolled
             diarrhea, malabsorption, significant small bowel resection or gastric bypass surgery,
             use of feeding tubes

          -  Major surgery within 28 days prior to randomization

          -  Patients with active and/or untreated central nervous system (CNS) cancer are not
             eligible. Patients with treated brain metastasis must have 1) documented radiographic
             stability of at least 4 weeks duration demonstrated on baseline contrast-enhanced CNS
             imaging (eg contrast-enhanced MRI of the brain) prior to randomization and 2) must be
             symptomatically stable and off steroids for at least 2 weeks before randomization.

          -  Known active infection with HIV or Hepatitis B or C virus

          -  Chronic treatment with corticosteroids or other immunosuppressive agents except (i)
             inhaled or topical steroids or replacement dose corticosteroids equivalent to ≤ 10 mg
             prednisone and (ii) patients receiving physiological doses of hydrocortisone for
             adrenal insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam Whiting</last_name>
    <role>Study Director</role>
    <affiliation>Calithera Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Administrator</last_name>
    <phone>650-870-1000</phone>
    <email>clinicaltrials@calithera.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clinical Admin</last_name>
    <email>clinicaltrials@calithera.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Rippe</last_name>
      <phone>520-694-9049</phone>
      <email>GRippe@uacc.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Montaser Shaheen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Highlands Oncology Group - Clinical Research Department</last_name>
      <phone>479-587-1700</phone>
    </contact>
    <contact_backup>
      <phone>1-479-936-9900</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UCLA Department of Medicine - Hematology/Oncology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Crosetti</last_name>
      <phone>310-825-7412</phone>
      <email>ACrosetti@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Sandy Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Haas</last_name>
      <phone>650-736-1252</phone>
      <email>dhaas@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Alice Fan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists- South</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>askSARAH</last_name>
      <phone>844-482-4812</phone>
    </contact>
    <contact_backup>
      <email>asksarah@sarahcannon.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ivor Percent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists- North</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>askSarah</last_name>
      <phone>844-482-4812</phone>
    </contact>
    <contact_backup>
      <email>asksarah@sarahcannon.com</email>
    </contact_backup>
    <investigator>
      <last_name>Vijay Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Cancer &amp; Blood Center, LLC</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Hodgson</last_name>
      <phone>706-353-2990</phone>
      <phone_ext>279</phone_ext>
      <email>jhodgson@universitycancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Centers, P.C.</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristine Parker, RN</last_name>
      <phone>770-333-2161</phone>
      <email>Kparker@ngoc.com</email>
    </contact>
    <investigator>
      <last_name>Steve McCune, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Mountain States Tumor Institute</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammie Eslinger</last_name>
      <phone>208-381-2774</phone>
      <email>eslinget@slhs.org</email>
    </contact>
    <investigator>
      <last_name>Benjamin Bridges, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine Simmons Cancer Institute</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krishna A. Rao, MD</last_name>
      <phone>217-545-7929</phone>
    </contact>
    <investigator>
      <last_name>Krishna A. Rao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkview Research Center</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhentao Zhang, MD, PhD</last_name>
      <phone>260-425-6800</phone>
      <email>Zhentao.Zhang@parkview.com</email>
    </contact>
    <contact_backup>
      <last_name>Parkview.com</last_name>
    </contact_backup>
    <investigator>
      <last_name>Zhentao Zhang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janelle Born, RN</last_name>
      <phone>319-356-4797</phone>
      <email>janelle-born@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Yousef Zakharia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute, Norton Healthcare Pavilion</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Adkisson, RN</last_name>
      <phone>502-629-5315</phone>
      <email>Pamela.Adkisson@nortonhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Arash Rezazadeh Kalebasty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinical Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Scuderi</last_name>
      <phone>504-703-2654</phone>
      <email>Heather.porter@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Marc Matrana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anne Arundel Medical Center Oncology and Hematology</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven DeMartino</last_name>
      <phone>443-481-4390</phone>
      <email>sdemartino@aahs.org</email>
    </contact>
    <investigator>
      <last_name>Jason Taksey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland, Greenebaum Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Besche</last_name>
      <phone>410-328-8610</phone>
      <email>mbesche@umm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Umgccc.org</last_name>
    </contact_backup>
    <investigator>
      <last_name>Arif Hussain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>800-865-1125</phone>
      <email>canceranswerline@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Ajjai Alva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro-Minnesota Community Oncology Research Consortium</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Wagner</last_name>
      <phone>952-993-1555</phone>
      <email>Elizabeth.wagner@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>David King, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Atkocius</last_name>
      <phone>314-747-1343</phone>
      <email>a.atkocius@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>James Hsieh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent Frontier Cancer Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Erhardt</last_name>
      <phone>406-238-6685</phone>
      <email>SVFCC-Research@sclhs.net</email>
    </contact>
    <investigator>
      <last_name>Patrick Cobb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Goodman, MD, PhD</last_name>
      <email>cccnregulatory@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Oscar Goodman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Gartrell, MD</last_name>
      <phone>718-405-8404</phone>
      <email>bgartrel@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Benjamin Gartrell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Silverberg</last_name>
      <email>Silverb1@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Chung-Han Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Benz</last_name>
      <phone>315-464-8253</phone>
      <email>benzp@upstate.edu</email>
    </contact>
    <investigator>
      <last_name>Bernard Poiesz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Smith, RN</last_name>
      <phone>330-492-3345</phone>
      <phone_ext>208</phone_ext>
      <email>csmith@gabrailcancercenter.com</email>
    </contact>
    <contact_backup>
      <last_name>www.gabrailcancercenter.com</last_name>
    </contact_backup>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Kastl</last_name>
      <phone>513-558-3545</phone>
      <email>kastla@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Karim Nagla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann B. Barshinger Cancer Institute / Lancaster General Hospital</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krista Budzik</last_name>
      <phone>717-544-0511</phone>
      <email>krbudzik@lghealth.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Brennan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charleston Hematology Oncology Associates,PA</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Patel, RN</last_name>
      <phone>843-577-6957</phone>
      <email>stephanie.patel@choasc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT/Erlanger Oncology &amp; Hematology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Department</last_name>
      <phone>423-778-3900</phone>
      <email>Jill.metcalf@erlanger.org</email>
    </contact>
    <investigator>
      <last_name>Robert M Graham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute - Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AskSARAH</last_name>
      <phone>844-482-4812</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johnny Walker</last_name>
      <phone>801-281-6864</phone>
      <email>jwalker@utahcancer.com</email>
    </contact>
    <investigator>
      <last_name>S. Kendall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Hospital and Clinics</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Woolston, RN</last_name>
      <phone>509-663-8711</phone>
      <phone_ext>5014</phone_ext>
      <email>Rebecca.woolston@confluencehealth.org</email>
    </contact>
    <investigator>
      <last_name>Lindsay Overton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>UWCCC Cancer Contact</last_name>
      <phone>800-622-8922</phone>
    </contact>
    <investigator>
      <last_name>Hamid Emamekhoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.calithera.com</url>
    <description>Calithera Biosciences Company website</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2017</study_first_submitted>
  <study_first_submitted_qc>May 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced, metastatic RCC</keyword>
  <keyword>RCC</keyword>
  <keyword>CB-839</keyword>
  <keyword>Everolimus</keyword>
  <keyword>CBE</keyword>
  <keyword>Glutaminase Inhibitor</keyword>
  <keyword>Glutaminase</keyword>
  <keyword>Tumor Metabolism</keyword>
  <keyword>Glutamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

